Neoadjuvant Tislelizumab + Nab-Paclitaxel Followed by Distal Ureterectomy for Ureteral Cancer

NCT07125547 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

35

Enrollment

OTHER

Sponsor class

Conditions

Ureteral Cancer
Neoadjuvant Therapy
PD-1 Inhibitor
Kidney-sparing
Tislelizumab
Nab-paclitaxel

Interventions

DRUG: PD-1 inhibitior
DRUG: Nab-paclitaxel
PROCEDURE: distal ureterectomy

Sponsor

Tianjin Medical University Second Hospital